Ann: Volpara Business Update, page-7

They have never been short of interesting ideas and technology, but I think the priority will remain on breast until they are in a sustainably comfortable cashflow position. I don't think the market will thank them if they turn around and start spending signficant money on the development of new products until they can prove it can be financed from operational cash flow and not via new equity. Partnership is always an option. In addition to the BAC there is also the lung products which are in the market and very interesting but the development of which have been de-emphasised over the last 18 months.